TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03087968
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
Study: NCT03661788
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day treatment interval: first week one placebo pill, second week two placebo pills
Study: NCT01551290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
Study: NCT01571908
Drug: Placebo perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
Study: NCT02120092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7x 300mg acetylsalicylic acid placebo
Study: NCT01550341
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
Study: NCT03049267
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
Study: NCT00002522
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03087968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04125056
Drug: Hydronidone Capsule(Specification: 30 mg / grain）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group
Study: NCT04125056
Drug: Hydronidone Capsule(Specification: 15 mg / grain）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group
Study: NCT02368912
Drug: Placebo single dose of dose levels 1-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, dose escalation, healthy young male
Study: NCT02368912
Drug: ASP1707 single dose fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, healthy young male
Study: NCT02368912
Drug: ASP1707 single dose fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, healthy young male
Study: NCT02368912
Drug: Placebo multiple dose of dose levels 1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, multiple dose escalation, healthy elderly male
Study: NCT02368912
Drug: Placebo multiple dose of dose levels 1-2
Normalized name: milk of magnesia 1.2 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, multiple dose escalation, healthy pre-menopausal female
Study: NCT02368912
Drug: Placebo parallel multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, dose escalation, healthy pre-menopausal female
Study: NCT03691623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension for 5 days
Study: NCT04350021
Drug: Capecitabine, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily
Study: NCT04338633
Drug: Conventional calcium hydroxide paste
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
Study: NCT04338633
Drug: Calcium hydroxide nanoparticle
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
Study: NCT04338633
Drug: Combined Calcium hydroxide with silver nanoparticle
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
Study: NCT01431937
Drug: GSK2018682
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Drug
Study: NCT01431937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02627287
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subcutaneously (s.c. under the skin) injection
Study: NCT00003671
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003671
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003671
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003671
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05081349
Drug: Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy
Study: NCT05081349
Drug: Hydroxycarbamide 500 Mg Oral Capsule
Normalized name: Hydroxycarbamide 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent
Study: NCT05081349
Drug: L-Carnitine, 250 Mg Oral Capsule
Normalized name: L-Carnitine, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: single agent
Study: NCT01304212
Drug: several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
Study: NCT01304212
Drug: ropivacaine,morphine chloride,epinephrine,ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
Study: NCT01304212
Drug: morphine ,ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
Study: NCT03817320
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose
Study: NCT03817320
Drug: Methotrexate (IT)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
Study: NCT03817320
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
Study: NCT00090142
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered orally as a single witnessed dose before exercise challenge
Study: NCT04185649
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
Study: NCT00037817
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg PO BID on days 4 through 34 of each cycle
Study: NCT01215110
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03926000
Drug: Control placebo (C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets one hour before the procedure as premedication.
Study: NCT01882010
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline solution daily subcutaneous injection 56 days
Study: NCT01626118
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules, 40 mg, TID
Study: NCT01626118
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules, 40 mg, BID
Study: NCT01626118
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules, 20 mg, TID
Study: NCT01626118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT01778049
Drug: BI 10773 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin placebo
Study: NCT01778049
Drug: BI 10773 / BI 1356
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Study: NCT01778049
Drug: BI 10773 / BI 1356
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin / Linagliptin 10/5 mg Dose FDC active
Study: NCT01778049
Drug: BI 10773 / BI 1356 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
Study: NCT01778049
Drug: BI 10773 / BI 1356 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Study: NCT01778049
Drug: BI 10773 / BI 1356 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
Study: NCT02249299
Drug: Sativex Oromucosal Spray
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
Study: NCT02249299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02928029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01574898
Drug: V0474 - A mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration
Study: NCT01574898
Drug: V0474 - B mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration
Study: NCT01574898
Drug: V0018 - B mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration
Study: NCT01574898
Drug: Niquitin® Fresh Mint 4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration
Study: NCT01900301
Drug: intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
Study: NCT03477851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9%NaCl i.m. simultaneous with sciatic nerve block
Study: NCT03600766
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
Study: NCT01872039
Drug: Perdipine injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01741142
Drug: ABT-436
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receiving ABT-436
Study: NCT01741142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receiving placebo
Study: NCT00348907
Drug: thermal cure
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
Study: NCT00348907
Drug: late thermal cure
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
Study: NCT02308527
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
Study: NCT01818258
Drug: ZDV+3TC+LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01564290
Drug: Placebo probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
Study: NCT01382303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet three times a day
Study: NCT00446472
Drug: Regranex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regranex gel will be used for a total of 16 weeks
Study: NCT00446472
Drug: Hydrogel
Normalized name: HYDROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo hydrogel will be applied for 16 weeks
Study: NCT03122353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle used as placebo
Study: NCT03216304
Drug: 20 mg rosuvastatin calcium period 1
Normalized name: rosuvastatin calcium 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)
Study: NCT03216304
Drug: 20 mg rosuvastatin calcium period 2
Normalized name: rosuvastatin calcium 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: - Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
Study: NCT03664674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection of placebo
Study: NCT02526823
Drug: R-CHOP/CHOPE or ABVD chemotherapy regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；
Study: NCT02526823
Drug: R-CDOP/CDOPE or DBVD chemotherapy regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；
Study: NCT02174523
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01509677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, once daily, oral administration in the morning after breakfast
Study: NCT02850263
Drug: Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
Study: NCT00826358
Drug: ABT-143
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once, please see Arm Description for more details.
Study: NCT00826358
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once, see Arm Description for more detail
Study: NCT00826358
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once, see Arm Description for more detail
Study: NCT00112411
Drug: Bronchodilator
Normalized name: Bronchodilator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03640052
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule before sleep
Study: NCT03640052
Drug: LTM1201L
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTM1201L capsule before sleep
Study: NCT03640052
Drug: LTM1201LN
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTM1201LN capsule before sleep
Study: NCT03640052
Drug: LTM1201LB
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTM1201LB capsule before sleep
Study: NCT03640052
Drug: LTM1201LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTM1201LD capsule before sleep
Study: NCT03502967
Drug: Hyperpolarized [1-13C] Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of study drug
Study: NCT03502967
Drug: Hyperpolarized [2-13C] Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of study drug
Study: NCT02685748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two pills twice a day (instead of aspirin and pantoprazole)
Study: NCT00328653
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03549871
Drug: Factor (FVIII or FIX) prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: Intravenous
Study: NCT01656343
Drug: Calcineurin inhibitors (CNI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Intervention
Study: NCT02867618
Drug: TGR-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
Study: NCT01054937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration
Study: NCT02311439
Drug: FOLFIRINOX + CRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator.
Study: NCT04163991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline for IV infusion
Study: NCT01632241
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Study: NCT01133626
Drug: Placebo Nasal Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal aerosol administered daily for 42 days of treatment
Study: NCT02403635
Drug: ASP2151
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00195520
Drug: Totelle®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01904149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single oral dose (first 8 hours)
Study: NCT01904149
Drug: Dexketoprofen-single dose
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen single oral dose (first 8 hours)
Study: NCT01904149
Drug: Dexketoprofen/Tramadol-single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen/Tramadol single oral dose (first 8 hours)
Study: NCT01904149
Drug: Dexketoprofen-multiple doses
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
Study: NCT01904149
Drug: Dexketoprofen/Tramadol-multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
Study: NCT03395951
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation of hemodynamics during diuretics treatment within clinical indication.
Study: NCT02238431
Drug: Lucrin depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
Study: NCT02227173
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00460954
Drug: Sinemet® controlled release (Carbidopa/levodopa)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02567682
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
Study: NCT02802241
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00246025
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsule, once a day, oral administration
Study: NCT03730961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT00524615
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg of spironolactone once daily or placebo for 2 months
Study: NCT01527513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments will be administered by oral route, once-daily, in the evening.
Study: NCT00004174
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00001155
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01767493
Drug: [18F]Florbetapir PET imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]Florbetapir and PET imaging
Study: NCT01598753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
Study: NCT01420874
Drug: FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
Study: NCT01119833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis